natgillin/translations-raw huggingface dataset:
However patients with hepatic impairment such as bilirubin &gt; 1.5 times the upper limit of normal and/or aminotransferase &gt; 3.0times the upper limit of normal (hepatic metastases absent) or &gt; 5.0 times the upper limit of normal (hepatic metastases present) have not been specifically studied.
Vendar pa bolnikov z okvarjenim delovanjem jeter, ki se kaže kot bilirubin &gt; 1,5-kratnik zgornje meje normalnih vrednosti in/ali aminotransferaza &gt; 3,0-kratnik zgornje meje normalnih vrednosti (brez zasevkov v jetrih) ali &gt; 5,0-kratnik zgornje meje normalnih vrednosti (z zasevki v jetrih), niso posebej preučevali.
However the largest benefit was observed in a predefined exploratory analysis in patients with EGFR activating mutations (n= 49) demonstrating a substantial PFS benefit (HR=0.10, 95% CI, 0.04 to 0.25; p &lt; 0.0001) and an overall survival HR of 0.83 (95% CI, 0.34 to 2.02).
Največjo korist pa so opazili pri bolnikih z EGFR- aktivirajočimi mutacijami (n = 49), za katere je bila eksplorativna analiza določena vnaprej, in pri katerih je bila korist v smislu preživentja brez napredovanja bolezni precejšnja (razmerje ogroženosti = 0,10, 95-% interval zaupanja: 0,04-0,25; p &lt; 0,0001), razmerje ogroženosti za celokupno preživetje pa 0,83 (95-% interval zaupanja: 0,34-2,02).
However the potential absorption and accumulation of sevelamer during long-term chronic treatment ( &gt; one year) cannot be totally excluded (see section 5.2).
Vendar pa možne absorpcije in akumulacije sevelamera v dolgotrajnem kroničnem zdravljenju ( &gt; eno leto) ni mogoče čisto izključiti (glejte poglavje 5.2).
However, 1,611 patients (804 bosentan- and 807 placebo-treated patients) with severe chronic heart failure (CHF) were treated for a mean duration of 1.5 years in a placebo- controlled study (study AC-052-301/302 [ENABLE 1 &amp; 2]).
Je pa v s placebom nadzorovani študiji (študija AC-052-301/302 [ENABLE 1 &amp; 2]) s povprečnim trajanjem zdravljenja 1,5 let sodelovalo 1611 bolnikov (804 bolniki so jemali bosentan, 807 bolnikov je prejemalo placebo) s hudim kroničnim srčnim popuščanjem (CHF – Chronic Heart Failure).
However, 1,611 patients (804 bosentan- and 807 placebo-treated patients) with severe chronic heart failure (CHF) were treated for a mean duration of 1.5 years in a placebo-controlled study (study AC-052-301/302 [ENABLE 1 &amp; 2]).
Je pa v s placebom nadzorovani študiji (študija AC-052-301/302 [ENABLE 1 &amp; 2]) s povprečnim trajanjem zdravljenja 1,5 let sodelovalo 1611 bolnikov (804 bolniki so jemali bosentan, 807 bolnikov je prejemalo placebo) s hudim kroničnim srčnim popuščanjem (CHF – Chronic Heart Failure).
However, a higher percentage of subjects in the cobicistat-boosted group had increases in total bilirubin &gt; 2 x ULN than those in the ritonavir-boosted group (88.0% versus 80.9%).
Vendar pa je imel višji odstotek bolnikov v skupini skupini zdravila, okrepljenega s kobicistatom, povišan skupni bilirubin &gt; 2 x ULN kot v skupini zdravila, okrepljenega z ritonavirjem (88,0 % v primerjavi s 80,9 %).
However, a post-exposure interval &gt; 1 hour does not preclude the administration and effective action of chelator with reduced efficiency.
Vseeno, pa interval &gt; 1 ure po izpostavljenosti ne izključuje dajanja in uspešnega delovanja kelatorja z zmanjšano učinkovitostjo.
However, a post-exposure interval &gt; 1 hour does not preclude the administration and effective action of chelator, even if with reduced efficiency.
Vseeno pa interval &gt; 1 ure po izpostavljenosti ne izključuje dajanja in uspešnega delovanja kelatorja, četudi z zmanjšano učinkovitostjo.
However, a post-exposure interval &gt; 1 hour does not preclude the administration and effective action of chelator with reduced efficiency.
Kljub temu pa interval &gt; 1 ure po izpostavljenosti ne izključuje dajanja in uspešnega delovanja kelatorja z zmanjšano učinkovitostjo.
However, a post-exposure interval &gt; 1 hour does not preclude the administration and effective action of chelator with reduced efficiency.
Seveda pa časovni interval &gt; 1 h po izpostavljenosti ne izključuje aplikacije in učinkovitega delovanja kelatorja z zmanjšano efektivnostjo.
However, a slight increase in abortion/embryonal-foetal death was observed with high systemic exposure ( &gt; 100 x human exposure) in the 50 mg/kg/day high-dose group compared to placebo and other low-dose groups.
Vendar pa so pri veliki sistemski izpostavljenosti ( &gt; 100-kratna izpostavljenost kot pri človeku) v visokoodmerni skupini 50 mg/kg/dan opažali rahel porast splavov oz. embrio-fetalnih smrti v primerjavi s skupino, ki je prejemala placebo in drugimi nizkoodmernimi skupinami.
However, at high MPAG plasma concentrations ( &gt; 100 µg/mL), small amounts of MPAG are removed.
Pri visokih koncentracijah mikofenolglukuronida v plazmi ( &gt; 100 μg/ml) se majhne količine mikofenolglukuronida vendarle odstranijo.
However, at high MPAG plasma concentrations ( &gt; 100µg/mL), small amounts of MPAG are removed.
Pri visokih koncentracijah mikofenolglukuronida v plazmi ( &gt; 100 µg/ml) se majhne količine mikofenolglukuronida vendarle odstranijo.
However, at high MPAG plasma concentrations ( &gt; °100 g/mL), small amounts of MPAG are removed.
Pri visokih koncentracijah mikofenolglukuronida v plazmi ( &gt; 100 µg/ml) se majhne količine mikofenolglukuronida vendarle odstranijo.
However, at high MPAG plasma concentrations ( &gt; °100°g/mL), small amounts of MPAG are removed.
Pri visokih koncentracijah mikofenolglukuronida v plazmi ( &gt; 100 µg/ml) se majhne količine mikofenolglukuronida vendarle odstranijo.
However, based on data from products known to prolong the QT-interval, a block of hERG potassium channels of &gt; 20 % may be clinically relevant.
Vendar pa je na podlagi podatkov zdravil, ki podaljšajo interval Q-T, blokiranje kalijevih kanalčkov hERG za &gt; 20 % lahko klinično pomembno.
However, clinical experience in patients &gt; 80 years of age is limited and caution should be exercised when treating this population.
Vendar pa so klinične izkušnje pri bolnikih nad 80 let omejene, zato je pri zdravljenju te populacije potrebna previdnost.
However, during the period of administration of filgrastim for PBPC mobilisation, filgrastim should be discontinued or its dosage should be reduced if the leukocyte counts rise to &gt; 70 x 109/L.
Če bolnik prejema filgrastim za izplavljanje PBPC, je treba z zdravljenjem s filgrastimom prenehati ali zmanjšati odmerek, če število levkocitov preseže vrednost &gt; 70 x 109/L.
However, during the period of administration of filgrastim for PBPC mobilisation, filgrastim should be discontinued or its dosage should be reduced if the leukocyte counts rise to &gt; 70 x 109/L.
Če bolniku prejema filgrastim za zbiranje matičnih celic v periferni krvi, je potrebno zdravljenje s filgrastimom prenehati ali pa, v primeru da število levkocitov preseže vrednost 70 x 109/l, zmanjšati odmerek.
However, during the period of administration of filgrastim for PBPC mobilisation, it should be discontinued or its dosage should be reduced if the leukocyte counts rise to &gt; 70 x 109/l.
Vendar pa je pri dajanju filgrastima za izplavljanje matičnih celic v periferno kri, treba z njegovim dajanjem prenehati ali njegov odmerek zmanjšati, če se število levkocitov poveča na &gt; 70 x 109/l.
However, elderly patients ( &gt; 70 years of age) appear to be at increased risk of neutropenia and thrombocytopenia (see section 4.4).
Vendar kaže, da je pri starejših bolnikih (starejših od 70 let) večje tveganje za nevtropenijo in trombocitopenijo (glejte poglavje 4.4).
However, elderly patients ( &gt; 70 years of age) appear to be at increased risk of neutropenia and thrombocytopenia (see section 4.4).
Vendar pa se zdi, da obstaja pri starejših bolnikih ( &gt; 70 let) povečano tveganje za pojav nevtropenije in trombocitopenije (glejte poglavje 4.4).
However, for patients with a body surface area &gt; 0.38 m2, the contents of between 1 to 7 vials will be required to produce the recommended daily dosage of clofarabine.
Vendar pa bo pri bolnikih s telesno površino &gt; 0,38 m2 za priporočeni dnevni odmerek klofarabina potrebnih 1 do 7 vial.
However, if the haemoglobin has increased &lt; 1 g/dl ( &lt; 0.62 mmol/l) and the reticulocyte count has increased &lt; 40 000 cells/µl above baseline, response is unlikely and treatment should be discontinued.
Če pa se je hemoglobina zvišal &lt; 1 g/dl (0,62 mmol/l) ali če se je število retikulocitov dvignilo &lt; 40 000 celic/µl nad osnovno vrednost, odziva verjetno ni in je treba zdravljenje prekiniti.
However, in field studies 10% of sero-negative dogs did not show seroconversion ( &gt; 0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies.
Študije na terenu so pokazale, da pri 10 % serološko negativnih psov ne pride do serološke konverzije ( &gt; 0,1 IU/ml) 3–4 tedne po enkratnem cepljenju proti steklini.
However, in field studies 10% of sero-negative dogs did not show seroconversion ( &gt; 0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies.
Študije na terenu so pokazale, da pri 10 % serološko negativnih psov ne pride do serološke konverzije ( &gt; 0,1 IU/ml) 3–4 tedne po enkratnem osnovnem cepljenju proti steklini.
However, in field studies 10% of sero-negative dogs did not show seroconversion ( &gt; 0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies.
Študije na terenu so pokazale, da pri 10 % serološko negativnih psov ne pride do serološke konverzije (≥ 0,1 IU/ml) 3–4 tedne po enkratnem cepljenju proti steklini.
However, in field studies 10% of sero-negative dogs did not show seroconversion ( &gt; 0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies.
Študije na terenu so pokazale, da pri 10 % serološko negativnih psov ne pride do serološke konverzije (≥ 0,1 IU/ml) 3–4 tedne po enkratnem osnovnem cepljenju proti steklini.
However, in field studies 10% of sero-negative dogs did not show seroconversion ( &gt; 0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies.
Študije na terenu so pokazale, da pri 10 % serološko negativnih psov ne pride do serološke konverzije (≥ 0,1 IU/ml) 3-4 tedne po enkratnem cepljenju proti steklini.
However, in field studies 10% of seronegative dogs did not show seroconversion ( &gt; 0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies.
Študije na terenu so pokazale, da pri 10 % serološko negativnih psov ne pride do serološke konverzije (≥ 0,1 IU/ml) 3–4 tedne po enkratnem cepljenju proti steklini.
However, in patients with liver iron concentration &lt; 7 mg Fe/g dw treated with deferasirox dispersible tablets (5 and 10 mg/kg) or deferoxamine (20 to 35 mg/kg), non-inferiority was not established due to imbalance in the dosing of the two chelators.
Pri bolnikih s koncentracijo železa v jetrih &lt; 7 mg Fe/g suhe teže, zdravljenih bodisi z deferasiroksom v obliki disperzibilnih tablet (5 in 10 mg/kg) ali deferoksaminom (20 do 35 mg/kg) pa neinferiornost ni bila ugotovljena zaradi neuravnoteženega odmerjanja obeh kelatorjev.
However, in patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) or end-stage renal disease requiring haemodialysis or peritoneal dialysis, bedaquiline concentrations may be increased due to alteration of active substance absorption, distribution, and metabolism secondary to renal dysfunction.
Pri bolnikih s hudo okvaro ledvic (očistek kreatinina &lt; 30 ml/min) ali s končno ledvično odpovedjo, zaradi katere je potrebno zdravljenje s hemodializo ali peritonealno dializo, lahko pride do zvišanja koncentracij bedakilina zaradi spremenjene absorpcije, porazdelitve in presnove učinkovine pri zmanjšani ledvični funkciji.
However, in rare cases severe hypertriglyceridaemia (triglycerides &gt; 1,000 mg/dl) has been reported which increases the risk of development of acute pancreatitis.
Vendar so v redkih primerih poročali o hudi hipertrigliceridemiji (trigliceridi &gt; 1.000 mg/dl), ki zvečuje nevarnost razvoja akutnega pankreatitisa.
However, patients with age &gt; 75 years are potentially at risk for a higher frequency of serious adverse reactions.
Vendar pa je pri bolnikih, starejših od 75 let, možno tveganje večje pogostnosti resnih neželenih učinkov.
However, patients with hepatic impairment, such as bilirubin &gt; 1.5-times the upper limit of normal and/or aminotransferase &gt; 3.0-times the upper limit of normal (hepatic metastases absent) or &gt; 5.0-times the upper limit of normal (hepatic metastases present), have not been specifically studied.
Vendar pa bolnikov z okvarjenim delovanjem jeter, ki se kaže kot bilirubin &gt; 1,5-kratnik zgornje meje normalnih vrednosti in/ali aminotransferaza &gt; 3,0-kratnik zgornje meje normalnih vrednosti (brez zasevkov v jetrih) ali &gt; 5,0-kratnik zgornje meje normalnih vrednosti (z zasevki v jetrih), niso posebej preučevali.
However, post-exposure prophylaxis for varicella and measles has been demonstrated with Varicella Vaccine live (Oka/Merck) and the measles-containing vaccines manufactured by Merck &amp; Co., Inc., respectively.
Dokazana pa je bila profilaksa s cepivom z živim virusom noric (Oka/Merck) po izpostavitvi noricam ter profilaksa s cepivi, ki vsebujejo cepivo proti ošpicam izdelovalca Merck &amp; Co., Inc., po izpostavitvi ošpicam.
However, since M-M-RVAXPRO has been shown to have safety and immunogenicity profiles similar to the previous formulation of the combined measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc., experience with this vaccine can be considered.
Ker pa se je pokazalo, da ima cepivo M-M-RVAXPRO podoben profil varnosti in imunogenosti kot prejšnja oblika kombiniranega cepiva proti ošpicam, mumpsu in rdečkam izdelovalca Merck &amp; Co., Inc., lahko upoštevamo izkušnje s tem cepivom.
However, subjects with baseline CD4 &gt; 100 cells/mm3, baseline HIV-1 RNA &lt; 5.0 log10 copies/ml, ≤ 10 prior ARVs, and/or other active ARVs in their OB regimen were more likely to achieve a HIV-1 RNA of &lt; 400 copies/ml (or &lt; 50 copies/ml) on either treatment (see Table 6).
Kakor koli so v obeh shemah zdravljenja bolniki z izhodiščnim CD4 &gt; 100 celic/mm3, izhodiščno HIV-1 RNA &lt; 5,0 log kopij/ml, z  10 predhodnimi protiretrovirusnimi zdravili in/ali drugimi aktivnimi protiretrovirusnimi zdravili v shemi optimiziranega temeljnega zdravljenja, verjetneje dosegli HIV-1 RNA &lt; 400 kopij/ml (ali &lt; 50 kopij/ml) (glejte preglednico 6).
However, the combination product is not recommended for patients with severe renal impairment (creatinine clearance &lt; 30 mL/minute).
Kljub temu pa kombinirano zdravilo ni priporočljivo za uporabo pri bolnikih s hudo ledvično okvaro (očistek kreatinina &lt; 30 ml/minuto).
However, the efficacy of Varicella Vaccine live (Oka/Merck) and the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc. has been demonstrated in numerous studies.
V številnih študijah pa so dokazali učinkovitost cepiva z živim virusom noric (Oka/Merck) in cepiva proti ošpicam, mumpsu in rdečkam izdelovalca Merck &amp; Co., Inc.
However, the incidences of decreases in serum calcium to &lt; 8.0 mg/dl (2.0 mmol/l) and serum phosphate to  2.0 mg/dl (0.65 mmol/l) were similar in both treatment groups.
Pojavnosti znižanja serumskega kalcija na &lt; 8,0 mg/dl (2,0 mmol/l) in serumskega fosfata na ≤ 2,0 mg/dl (0,65 mmol/l) pa sta bili v obeh skupinah podobni.
However, the occurrence of cytopenias was also clearly dependent on the stage of the disease, the frequency of grade 3 or 4 neutropenias (ANC &lt; 1.0 x 109/l) and thrombocytopenias (platelet count &lt; 50 x 109/l) being between 4 and 6 times higher in blast crisis and accelerated phase (59-64% and 44-63% for neutropenia and thrombocytopenia, respectively) as compared to newly diagnosed patients in chronic phase CML (16.7% neutropenia and 8.9% thrombocytopenia).
Nevtropenija 3. ali 4. stopnje (ANC &lt; 1,0 x 109/l) in trombocitopenija (koncentracija trombocitov &lt; 50 x 109/l) sta bili štirikrat do šestkrat pogostejši v blastni krizi in pospešeni fazi (nevtropenija 59–64 % in trombocitopenija 44–63 %) kot pri na novo diagnosticiranih bolnikih v kronični fazi KML (nevtropenija 16,7 % in trombocitopenija 8,9 %).
However, thoughts of harming others, physical assault or threatening behaviour were observed in some patients ( &lt; 1% in perampanel clinical studies).
Vendar pa so pri nekaterih bolnikih opazili razmišljanja o poškodovanju drugih, fizičnemu napadu ali grozečemu vedenju ( &lt; 1 % v kliničnih študijah s perampanelom).
HR 0.53; p &lt; 0.0001
p &lt; 0,0001
HR Hazard ratio (hazard ratios &lt; 1 favour IRESSA)
ROG razmerje ogroženosti (razmerja ogroženosti &lt; 1 so v korist zdravila IRESSA)
Human plasma protein binding of netupitant and its two major metabolites M1 and M3 is &gt; 99% at concentrations ranging from 10 to 1500 ng/mL.
Vezava netupitanta in njegovih dveh glavnih presnovkov M1 in M3 na beljakovine v človeški plazmi je pri koncentracijah od 10 ng/ml do 1500 ng/ml večja od 99 %.
Humira was assessed in a multicenter, randomised, double-blind clinical trial designed to evaluate the efficacy and safety of induction and maintenance treatment with doses dependent on body weight ( &lt; 40 kg or ≥ 40 kg) in 192 paediatric subjects between the ages of 6 and 17 (inclusive) years, with moderate to severe Crohn´s disease (CD) defined as Paediatric Crohn's Disease Activity Index (PCDAI) score &gt; 30.
Zdravilo Humira je bilo ocenjeno v multicentrični, randomizirani, dvojno slepi klinični študiji, ki je bila zasnovana za oceno učinkovitosti in varnosti uvodnega in vzdrževalnega zdravljenja z odmerki, odvisnimi od telesne mase ( &lt; 40 mg ali ≥ 40 mg) pri 192 pediatričnih bolnikih med 6. in 17. (vključno) letom starosti, z zmerno do hudo Crohnovo boleznijo (CD) definirano kot vrednost indeksa Pediatric Crohn’s Disease Activity Index (PCDAI) &gt; 30.
Humira/methotrexate combination therapy was clinically and statistically superior to methotrexate (p &lt; 0.001) and Humira monotherapy (p &lt; 0.001) in achieving a low disease state in patients with recently diagnosed moderate to severe rheumatoid arthritis.
Za doseganje nizkega stanja bolezni pri bolnikih z nedavno diagnosticiranim zmernim do hudim revmatoidnim artritisom je bila kombinirana terapija z zdravilom Humira in metotreksatom klinično in statistično boljša od monoterapije z metotreksatom (p &lt; 0,001) in monoterapije z zdravilom Humira (p &lt; 0,001).
Hypercalcaemia &gt; 12 mg/dl (2.99 mmol/l).
Hiperkalcemija &gt; 12 mg/dl (2,99 mmol/l)
Hyperkalaemia, hyponatremia or Na⁺/K⁺ ratio &lt; 27: Decrease the Zycortal dosing interval by 2–3 days or increase the dose.
Hiperkaliemija, hiponatriemija ali razmerje Na⁺/K⁺ &lt; 27: Zmanjšajte interval odmerjanja zdravila Zycortal za 2–3 dni ali povečajte odmerek.
Hypersensitivity reactions have been reported in &lt; 1% of patients treated with dolutegravir in clinical studies, and were characterized by rash, constitutional findings, and sometimes, organ dysfunction, including severe liver reactions.
V kliničnih študijah poročajo o preobčutljivostnih reakcijah pri &lt; 1% bolnikov, zdravljenih z dolutegravirjem, za katere so bili značilni izpuščaj, sistemski pojavi, včasih pa tudi motnje v delovanju organov, vključno s hudimi jetrnimi reakcijami.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Docetaxel must not be used in patients with baseline neutrophil count of &lt; 1,500 cells/mm3.
Preobčutljivost za zdravilno učinkovino ali katerokoli pomožno snov, navedeno v poglavju 6.1. Docetaksela se ne sme uporabljati pri bolnikih z izhodiščnim številom nevtrofilcev &lt; 1.500 celic/mm3.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Patients with baseline neutrophil count of &lt; 1,500 cells/mm3.
Preobčutljivost na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1. Bolniki z izhodiščnim številom nevtrofilcev &lt; 1.500 celic/mm3.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Patients with baseline neutrophil count of &lt; 1,500 cells/mm3.
Preobčutljivost za zdravilno učinkovino ali katerokoli pomožno snov, navedeno v poglavju 6.1. Bolniki z izhodiščnim številom nevtrofilcev &lt; 1.500 celic/mm3.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Patients with baseline neutrophil count of &lt; 1,500 cells/mm3.
Preobčutljivost za zdravilno učinkovino ali katerokoli pomožno snov, navedeno v poglavju 6.1. Bolnikih z izhodiščnim številom nevtrofilcev &lt; 1.500 celic/mm3.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Patients with baseline neutrophil count of &lt; 1,500 cells/mm3.
Preobčutljivost na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Pulmonary hypertension with a systolic pulmonary artery pressure &gt; 90 mm Hg.
Preobčutljivost na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1. Pljučna hipertenzija s sistoličnim tlakom v pljučni arteriji &gt; 90 mm Hg.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Severe renal impairment (creatinine clearance &lt; 30 ml/min) (see sections 4.2 and 5.2).
Preobčutljivost za zdravilno učinkovino ali katerokoli pomožno snov, navedeno v poglavju 6.1. Huda ledvična okvara (kreatininski očistek &lt; 30 ml/min) (glejte poglavji 4.2 in 5.2).
Hypersensitivity-type reactions, including skin rash, urticaria, angioedema, dyspnoea, erythaema, flushing, and hypotension occurred on initial or subsequent treatment with Neulasta (uncommon [≥ 1/1,000 to &lt; 1/100]).
Med začetnim ali nadaljnjim zdravljenjem z zdravilom Neulasta so se pojavile reakcije preobčutljivostne vrste, vključno z izpuščajem na koži, urtikarijo, angioedemom, dispnejo, eritemom, zardevanjem in hipotenzijo (občasno [≥ 1/1.000 do &lt; 1/100]).
Hypersensitivity-type reactions, including skin rash, urticaria, angioedema, dyspnoea, erythaema, flushing, and hypotension occurred on initial or subsequent treatment with Ristempa (uncommon [≥ 1/1,000 to &lt; 1/100]).
Med začetnim ali nadaljnjim zdravljenjem z zdravilom Ristempa so se pojavile reakcije preobčutljivostne vrste, vključno z izpuščajem na koži, urtikarijo, angioedemom, dispnejo, eritemom, zardevanjem in hipotenzijo (občasno [≥ 1/1.000 do &lt; 1/100]).
Hypogammaglobulinaemia ( &lt; 4 g/l) in patients after allogeneic haematopoietic stem cell transplantation
Hipogamaglobulinemija( &lt; 4 g/l) pri bolnikih po alogenski presaditvi krvotvornih matičnih celic
hypogammaglobulinaemia (IgG &lt; 400 mg/dl) or IgA deficiency (IgA &lt; 10 mg/dl)
hipogamaglobulinemijo (IgG &lt; 400 mg/dl) ali pomanjkanjem IgA (IgA &lt; 10 mg/dl),
Hypokalaemia, hypernatremia or Na⁺/K⁺ ratio &gt; 32: Decrease the Zycortal dose.
Hipokaliemija, hipernatriemija ali razmerje Na⁺/K⁺ &gt; 32: Zmanjšajte odmerek zdravila Zycortal.
Hypophysitis occurred in 17 (0.6%) patients, including Grade 2, 3 or 4 cases in 6 (0.2%), 8 (0.3%) and 1 ( &lt; 0.1%) patients, respectively, receiving pembrolizumab.
Hipofizitis se je pojavil pri 17 bolnikih (0,6 %), ki so prejemali pembrolizumab; pri 6 bolnikih (0,2 %) je bil 2. stopnje, pri 8 bolnikih (0,3 %) 3. stopnje in pri 1 bolniku ( &lt; 0,1 %) 4. stopnje.
Hypotension was also uncommon ( &lt; 1%) during combination therapy with other antihypertensive agents.
Hipotenzijo so občasno (pri manj kot 1 %) opažali tudi med zdravljenjem v kombinaciji z drugimi antihipertenzivnimi zdravili.
Hypotension was also uncommon ( &lt; 1%) during combination therapy with other antihypertensive medicinal products.
Hipotenzijo so občasno (pri manj kot 1 %) opažali tudi med zdravljenjem v kombinaciji z drugimi antihipertenzivnimi zdravili.